| Literature DB >> 34064769 |
Sami El Deeb1, Camilla Fonseca Silva2, Clebio Soares Nascimento Junior2, Rasha Sayed Hanafi3, Keyller Bastos Borges2.
Abstract
This work reviews the literature of chiral capillary electrokinetic chromatography from January 2016 to March 2021. This is done to explore the state-of-the-art approach and recent developments carried out in this field. The separation principle of the technique is described and supported with simple graphical illustrations, showing migration under normal and reversed polarity modes of the separation voltage. The most relevant applications of the technique for enantioseparation of drugs and other enantiomeric molecules in different fields using chiral selectors in single, dual, or multiple systems are highlighted. Measures to improve the detection sensitivity of chiral capillary electrokinetic chromatography with UV detector are discussed, and the alternative aspects are explored, besides special emphases to hyphenation compatibility to mass spectrometry. Partial filling and counter migration techniques are described. Indirect identification of the separated enantiomers and the determination of enantiomeric migration order are mentioned. The application of Quality by Design principles to facilitate method development, optimization, and validation is presented. The elucidation and explanation of chiral recognition in molecular bases are discussed with special focus on the role of molecular modeling.Entities:
Keywords: Quality by Design; capillary electrophoresis; capillary electrophoresis-mass spectrometry; chiral capillary electrokinetic chromatography; chiral recognition; chiral selector; enantiomeric impurity; enantiomers; enantioseparation; molecular modeling
Year: 2021 PMID: 34064769 PMCID: PMC8151978 DOI: 10.3390/molecules26102841
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Simple representative schematic diagram of CEKC normal polarity mode of the separation voltage separating a basic ionized enantiomeric racemate (R+ and S+) using CS in the BGE. Pink and green arrows show the apparent mobility (µapp) of the enantiomeric pair and the mobility of the EOF (µEOF), respectively. The blue arrows show the difference in the speed of the migration of enantiomers upon interaction with the CS. µapp of the CS would be according to its charge.
Figure 2Simple representative schematic diagram of CEKC under reversed polarity mode of the separation voltage with a negatively charged chiral selector and a basic ionized enantiomeric pair (R+ and S+). Pink and green arrows show the apparent mobility (µapp) of the enantiomeric pair and the mobility of the EOF (µEOF), respectively. The blue arrows show the difference in the speed of the migration of enantiomers upon interaction with the CS. Complexed enantiomers will migrate in the direction of the anode (here the outlet), due to interaction with the negatively charged CSs, which have strong µapp in the direction of anode.
Figure 3The proportion of application of the various chiral selectors in CE in 2015–2019 (incomplete statistics). Reprinted with permission from reference [51].
Figure 4Electropherograms that correspond to the enantiomeric separation of a standard solution (40 mg/mL) and cream samples of econazole and sulconazole. CE conditions: 50 mM phosphate buffer pH 2.5 containing mixtures of (A) 5 mM hydroxypropyl-β-CD with 20 mM tetrabutylammonium-L-lysine at 25 °C; (B) 2 mM hydroxypropyl-β-CD with 25 mM tetrabutylammonium-L-lysine at 15 °C. Other conditions: Uncoated fused silica capillary, 50 μM i.d. × 48.5 cm (40 cm of effective length); UV detection at 200 nm; applied voltage, 30 kV; injection by pressure, 50 mbar for 10 s. Reprinted with permission from [92].
List of representative works published between 2016 and March 2021 dealing with the application of CEKC in enantiomeric separation and determination of enantiomeric compounds from different fields.
| Analyte | Matrix | Separation Conditions | Detection | LOD/LOQ | Ref. |
|---|---|---|---|---|---|
| Cathinone derivatives | Human hair | Preconcentration by solid phase extraction, fused silica capillary of 50 µm i.d. and 80 cm total length, separation voltage of 35 kV, BGE of 80 mM disodium phosphate at pH 2.5, β-CD as CS | DAD at 200 nm | 0.02 ng/mg | [ |
| Proteinogenic amino acids | Cerebrospinal fluid | Derivatization by 9-fluorenylmethyl chloroformate fused silica capillary of 50 µm i.d. with a length of 70 cm to the detector and 80 cm of total length, separation voltage of 35 kV, BGE of 50 mM ammonium bicarbonate at pH 8 containing 15% ( | ESI-MS | 0.9 µM | [ |
| Tedizolid | Pharmaceutical formulation | Fused silica capillary of 45 cm (effective length 35 cm) × 25 µm i.d., separation voltage of 12 kV, BGE of 37.5 mM heptakis-(2,3-diacetyl6-sulfo)-β-CD dissolved in 50 mM formic buffer pH 4.0 with the addition of acetonitrile (81.4:18.6, | DAD at 200 nm | - | [ |
| Radezolid | Pharmaceutical preparation | Fused silica capillary of 45 total length and 35 cm effective length and 25 µm i.d., separation voltage −28 kV, BGE of 40 mM heptakis(2,3-di- | DAD at 265 nm | - | [ |
| Methadone | Exhaled breath condensate | Fused silica capillary of 50 cm length, 41.5 cm effective length, and 50 µm i.d., separation voltage of 25 kV, BGE of 150 mM phosphoric acid-tetraethylammonium at pH 2.5 containing 30% ( | DAD at 200 nm | - | [ |
| Colchicine | Pharmaceutical preparation | Fused silica capillary 58.5 cm (50 cm effective length) × 50 μm i.d., separation voltage of 20 kV, 50 mM or 25 mM borate buffer pH 9.0 using succinyl-γ-cyclodextrin or sulfated-γ-CD | UV at 243 nm | 0.3 mg/mL | [ |
| Praziquantel | Pharmaceutical preparation | Fused silica capillary of 50 µm i.d., 48.5 cm total and 40 cm effective length, separation voltage of 15 kV, BGE of 50 mM phosphate buffer pH 2.0, supplied with 15 mM sulfated-β-CD | DAD at 210 nm | 0.75 µg/mL | [ |
| Glycopyrrolate | Rat plasma | Online preconcentration by cation-selective exhaustive injection-sweeping, fused silica capillary (40.2 cm × 75 μm), separation voltage of −20 kV, BGE 30 mM phosphate solution at pH 2.0 containing 20 mg/mL sulfated-β-CD and 5% acetonitrile | DAD at 200 nm | 2.0 ng/mL | [ |
| Brompheniramine | Rat plasma | Online preconcentration by cation-selective exhaustive injection and sweeping, fused silica capillary of the total length of 50 cm (effective length 40 cm) × 50 µm i.d., separation voltage of −20 kV, BGE in 50 mM phosphate buffer pH 3.5, containing 10% ( | UV at 210 nm | - | [ |
| Ivabradine | Pharmaceutical formulation | Fused silica capillary of 58.5 cm (50 cm to the detector window) × 50 µm i.d., separation voltage of −30 kV, BGE of 5 mM tetrabutylammonium-aspartic acid in 50 mM formate buffer pH 2.0 containing 4 mM sulfated-γ-CD | UV at 200 nm | 0.22 and 0.28 µg/mL | [ |
| Lansoprazole and rabeprazole | Pharmaceutical preparations | Fused silica capillary of 48 cm total, and 40 cm effective length and 50 μm i.d., separation voltage of +20 kV, BGE for lansoprazole: 25 mM phosphate buffer pH 7, 10 mM sulfobutyl-ether-β-CD/20mM γ-CD, +20 kV voltage; BGE for rabeprazole: 25 mM phosphate buffer pH 7, 15 mM sulfobutyl-ether-β-CD/30 mM γ-CD | UV at 210 nm | 2 and 2 µg/mL | [ |
| Pheniramine | Rat plasma | Online preconcentration by large volume sample stacking and sweeping, fussed silica capillary of a total length of 50 cm (effective length 40 cm) × 50 μm i.d., separation voltage of −20 kV, BGE of 30 mM phosphate buffer at pH 3.0 with 30 mg/mL sulfated-β-CD | UV at 262 nm | - | [ |
| Phenothiazines | Urine sample | Preconcentration by solid phase extraction, fused silica capillary of 75 µm i.d. and 365 µm o.d., separation voltage from 10 to 12 kV, BGE of 75 mM phosphate buffer pH 3.0 and 0.9% poly (diallyldimethylammonium chloride), hydroxypropyl-γ-CD as a CS. | UV at 254 nm | 2.1 to 6.3 nM- | [ |
| Six phenoxy acid herbicides (Fenoprop 1, Fenoprop 2, Mecoprop 1, Mecoprop 2, Dichlorprop 1, Dichlorprop 2 | Mixture of herbicides | Fused silica capillary of 58.5 cm total length and 50 cm length to the detector and 50 µm i.d., separation voltage of 25 kV, BGE of 50 mM phosphate buffer pH 7.0, dual CD (4 mM hydroxyl--β-CD and 16 mM heptakis(2,3,6-tri- | DAD at 200 nm for mecoprop, chlorprop, and 210 nm for fenoprop | - | [ |
| Homocysteine and cysteine | Stock standard solutions in borate buffer | Derivatization by 9-fluorenylmethyl chloroformate, fused silica capillary of 58.5 cm total length and 50 cm effective length and 50 µm i.d., separation voltage 20 kV, BGE for homocysteine: 2 mM γ-CD +5 mM L-Carnitine C1NTf2 in borate buffer pH 9.0, BGE for Cysteine: 2 mM γ-CD +5 mM L-CarnitineC1Lac in phosphate buffer pH 7.0 | DAD at 210 nm | - | [ |
| Amlodipine | Pharmaceutical formulation | Fused silica capillary of 48 cm length (40 cm effective length) ×50 μm i.d., separation voltage of 25 kV, BGE of 25 mM phosphate buffer pH 9.0, 15 mM carboxymethyl-β-CD | UV at 230 nm | S 0.27 and R 0.32 µg/mL | [ |
| L/D-Asp, L/D-Glu, and L/D-Ser | Bone cell lines (murine osteocytes and osteoblast | Derivatization by 4-fluoro-7-nitro-2,1,3-benzoxadiazole, capillary fused silica with 75 μm i.d. and a total length of 60 cm, separation voltage of 30 kV, BGE 137.5 mM borate buffer pH 10.25 and 12.5 mM β-CDs | LIF at λex = 488 nm and λem = 522 nm | 0.25 µmol/L | [ |
| Venlafaxine | Pharmaceutical preparations | Fused silica capillary of 30 cm length (effective length 22 cm) × 50 µm, separation voltage of 25 kV, BGE of 25 mM phosphate buffer pH 2.5, 10 mM carboxymethyl-β-CD | UV at 230 nm | 0.07 and 0.06 mg/mL | [ |
| Methylparaben, ethylparaben, propylparaben, butylparaben, isobutylparaben, sorbic acid, benzoic acid, p-hydroxybenzoic acid | Pharmaceutical preparations | Online preconcentration by large volume sample stacking, fused silica capillary of 75 µm i.d. × 50 cm length, separation voltage 25 kV, BGE of 25 mM tetraborate pH 9.3 and α-CD | UV at 195 nm for ethylparaben, benzoic acid, and p-hydroxybenzoic acid, at 296 nm for methylparaben, propylparaben, butylparaben, and isobutylparaben, at 254 nm for sorbic acid at 254 nm. | 0.8 to 5 ng/mL | [ |
| L-Panthenol dexapanthenol | Pharmaceutical and cosmetic formulations | Fused silica capillary of a total length of 58.5 cm (50 cm effective length) and 50 µm i.d., separation voltage of 30 kV, BGE of 25 mM (2-carboxyethyl)-β-CD in 100 mM borate buffer pH 9.0 | UV at 205 nm | 1.0 and 4.0 mg/L | [ |
Figure 5Representative schematic illustration of enantioseparation by CEKC applying PFT for separating a basic ionized enantiomeric pair (R+ and S+) using CS in the BGE. Filling the CS (A), injecting the enantiomeric compound (B), and conducting the run with a vial contain BGE (C). Pink, yellow and green arrows show the apparent mobility (µapp) of the enantiomeric pair, the CS, and the mobility of the EOF (µEOF), respectively. The µapp of the CS is also in the direction of the cathode, but the migration speed of the CS is very slow compared to the migration speed of the two enantiomers; thus, the enantiomers can pass the CS plug rapidly. The blue arrows show the difference in the speed of the migration of enantiomers upon interaction with the CS.
Figure 6Representative schematic illustration of enantioseparation by CEKC applying counter migration technique for separating basic ionized enantiomeric pair (R+ and S+) using CS in the BGE. Filling the CS (A), injecting the enantiomeric compound (B), and conducting the run with a vial contain BGE (C). Pink, yellow and green arrows show the apparent mobility (µapp) of the enantiomeric pair, the CS, and the mobility of the EOF (µEOF), respectively. The CSs will have µapp toward the anode and will migrate to the opposite direction of the detector. The blue arrows show the difference in the speed of the migration of enantiomers upon interaction with the CS.
Figure 7ECD spectra of tryptophan (Trp), N-(tert-Butoxycarbonyl)-valine (Boc-Val), and ibuprofen (IP) with different enantiomeric excess value (ee% value). Enantiomers of each compound have opposite signals. Reprinted with permission from reference [138].
Figure 8Schematic representation of the chiral discrimination process by CDs. In (a), a system is shown in which the CDs migrate in the opposite direction to the EOF, so that the enantiomer involved in the more stable complex ((S)-Enantiomer@CD, correlated with ΔG1), has a longer time of migration. In (b), a system is shown in which the CDs migrate in the same direction as the EOF, so that the enantiomer involved in the more stable complex ((R)-Enantiomer@CD, correlated with ΔG2), presents a shorter migration time.
Summary of DoE based CEKC methods: Full factorial Design, (FFD, full factorial design; fFD, fractional factorial design; CCD, Central Composite Design; BBD, Box-Behnken Design; MCS, Monte Carlo Simulation, PBD, Placket Burman Design; Rs, resolution; t, migration time, PhB, phosphate buffer; OFAT, One-factor-at-a time).
| Application | Screening Design | Screened Factors | Optimization Design | CMPs | CQAs and ATP | Optimum Conditions | Software | Ref. |
|---|---|---|---|---|---|---|---|---|
| Enantioseparation of donepezil, rivastigmine, ketoconazole, itraconazole, fluconazole, sertaconazole | None | Type of CD (highly sulfated α, γ-CDs, hydroxyl propyl-β-CD, and sulfobutyl-ether-β-CD) | FFD (32) | pH, % CD | Rs; t | BGE: 50 mM phosphate-triethanolamine, 15 kV and 25 °C, pH 2.5 at low % highly sulfated-γ-CD or high % sulfobutyl-ether-β-CD | Minitab17 (USA) | [ |
| Chiral purity of pregabalin as dansyl derivative | D-optimal | BGE, pH, concentration of chiral selector, voltage, temperature. | Face-centered CCD and MCS | All screened factors | Rs; t Determine impurities at ≤0.015% S-eutomer | BGE: 100 mM PhB, pH 2.5, 40 mg/mL heptakis (2,3,6-tri- | MODDE 11 (Sweden) | [ |
| Chiral purity of cinacalcet | Ishikawa fishbone diagram and CNX tool | Type of CD: (2-carboxyethyl)-β-CD and (2-hydroxypropyl)-γ-CD | BBD and MCS | Voltage, buffer pH, % methanol, CD concentration | Rs; t Determine impurities at ≤0.1% R-eutomer | BGE: 150 mM PhB pH 2.70, 3.1 mM HPγCyD; 2.00% | MODDE 10 (Sweden) | [ |
| Chiral purity of dexmedetomidine | FFD | Type of CD (native α-CD, β-CD, γ-CD, neutral and charged derivatives), buffer type, addition of triethanolamine | Face-centered CCD | Voltage, temperature, buffer pH and concentration, CD concentration | Rs; t Determine impurities at 0.1% eutomer | BGE: 50 mM PhB pH 6.5, 40 mg/mL sulfated β-CD at 17 °C and 10 kV | MODDE 11 (Sweden) | [ |
| Chiral purity of levomepromazine | fFD | Type of CD (charged α-CD, β-CD; γ-CD, and its neutral derivative hydroxypropyl-γ-CD). Type of buffer. | Face-centered CCD, MCS | CD concentration, buffer pH and concentration temperature, voltage | Rs; t; absence of separation of sulfoxide diastereomers. | 100 mM citric acid buffer pH 2.85, 3.6 mg/mL hydroxypropyl-γ-CD, at 15 °C and 25 kV. | MODDE 11 (Sweden) | [ |
| Chiral purity of levodropropizine | OFAT | Type of CD: sulfated-α-CD; carboxymethyl-α-CD; succinyl-β-CD; Sulfated-β-CD | Face-centered CCD; MCS | CD concentration, % propan-2-ol; temperature; voltage | Rs; t; max analyses time 20 min. Quantify 0.5% of dextrodropropizine and 1-phenylpiperazine maximum analysis time of 20 min | 25 mM PhB pH 7.0, 23.5 mg/mL sulfated-β-CD and 10% propan-2-ol at 16.3 °C and 16.5 kV | MODDE 12 (Sweden) | [ |
| Enantiosepartion of venlafaxine | OFAT | Type of CD (neutral α-CD, β-CD, γ-CD, hydroxypropyl-β-CD, randomly methylated-β-CD, heptakis(2,6-di- | Face-centered CCD | CD concentration, BGE concentration, temperature, voltage, injection pressure | Rs; t | 10 mM carboxymethyl-β-CD; pH 2.5; at 15 °C and 25 kV | Design Expert 7.0 | [ |
List of representative works published between 2016 and March 2021 that deal with the study of chiral discrimination by CDs for EMO prediction or confirmation in CEKC.
| Analyte | CDs | Separation Conditions | Theoretical Methodology | Evidence of Interactions | Ref. |
|---|---|---|---|---|---|
| Tramadol | Sulfated-β-CD, carboxymethyl-β-CD | Phosphate buffer 125 mM (pH 10), 20 kV, 30 mbar/4 s, | Semiempirical PM3/DFT (B3LYP/6-31G+(d,p))/water solvent (PCM) | Hydrogen bonds | [ |
| Bupropion and hydroxybupropion | sulfated-β-CD | BGE phosphate 75 mM pH 7.0, 15 kV, 30 mbar/4 s, | Molecular dynamics simulations with AMBER/DFT force field (B97D(6-31G(d,p))/water solvent (SMD) | Hydrogen bonds | [ |
| Clenpenterol | β-CD/heptakis(2,3-di- | Phosphate buffer 50 mM pH 2.0 | Molecular dynamics simulations (100 ns trajectories) using amber force field | Van der Waals interactions, hydrogen bonds, and desolvation energy | [ |
| Quinurenine | α-CD, mono-6A-deoxy-6-(1-allylimidazolium)-β-CD chloride, and their mixture | Borax buffer 50 mM pH 9.0, 15 kV, 50 mbar/5 s, 25 °C, detection at 226 nm | Molecular docking/molecular mechanics MM2 | Hydrogen bonds | [ |
| Medetomidine | β-CD, γ-CD, Sulfated-β-CD and highly sulfated-β-CD | Phosphate buffer 50 mM pH 2.5, 20/−20 kV | Molecular dynamics simulations in water (TIP3P/12 Å, 100 ns trajectories) and use of amber force field | Hydrogen bonds | [ |
| Citalopram | Carboxymethyl-β-CD, | Phosphate buffer 25 mM pH 7.0, 15 kV, 50 mbar/1 s, 17.5 °C, detection at 240 nm | Semiempirical RM1/DFT M06-2X-D3(6-31G**)/water solvent by SM8 method | Details of structural analysis were not provided | [ |
| Asenapine | β-CD | TRIS-acetate buffer 160 mM pH 3.5, 15 kV, 50 mbar/4 s, 20 °C | Semiempirical PM3/DFT PBE def2-SVP/water solvent by COSMO method | Hydrogen bonds | [ |
| Sutezolid | heptakis-(2,3-diacetyl-6-sulfo)-β-CD | NACE buffer (methanol: acetonitrile: trifluoroacetic acid), 25 kV, 0.5 psi/5 s, 22 °C, detection at 200 and 258 nm | DFT/B3LYP(6-31G*)/water solvent (TIP3/14 Å) (Amber 14 molecular dynamics simulations (MM-GBSA/MMPBSA, trajectories up to 500 ns) | Hydrogen bonds | [ |
| Oxybutynin, clenbuterol, salbutamol and peneiclidine | heptakis-(2,3-diacetyl-6-sulfo)-β-CD | BGE TRIS-H3PO4 50 mM pH 2.5, 10 kV, 10 mbar/3 s, detection at 210 nm | Molecular Mechanics Powell Method (Strength Field Tripos)/Molecular Dynamics Simulations with LGA Algorithm | Hydrogen bonding, nonclassical hydrogen bonding and π-S | [ |
| Rasagiline | Sulfobutyl-ether-β-CD | Glycine-HCl buffer 50 mM pH 2.0, 12 kV, 25 mbar/2 s, 35 °C, detection at 200 nm | Molecular docking simulations/implicit solvency of Generalized Born | Van der Waals interactions, hydrogen bonds, and type-π | [ |
| Ofloxacin | Methylated-β-CD | Phosphate buffer 50 mM pH 3.1, 20 kV, 50 mbar/5 s, 20 °C, detection at 276 nm | Molecular Mechanics MM2 | Van der Waals interactions and electrostatic interactions (interactions of loads, dipoles, and quadrupoles) | [ |
| Bronpheniramine, chlorpheniramine and pheniramine | heptakis {2,6-di- | Phosphate buffer 120 mM pH 2.5–4.0, 20 kV, 20 psi, 20 °C, detection at 210 nm | Hybrid method ONIOM2: Semiempirical PM3/DFT (B3LYP/6-31G(d,p)) | Van der Waals interactions and electrostatic interactions | [ |
| Acebutelol | heptakis-(2,3-diacetyl-6-sulfo)-β-CD/heptakis(2,3-di- | Phosphate buffer 100 mM pH 3.0 and ammonium format 0.75 mM, 25 kV, 50 mbar/3 s, 15 °C, detection at 230 nm. | Molecular dynamics simulations with general amber force field with AM1-BCC load. For purpose solvent model IEFPCM (aqueous solution and methanol solution) | Hydrophobic effect and hydrogen bonds | [ |
| Amlodipine | carboxymethyl-β-CD | BGE TRIS-H3PO4 20 mM pH 3.5, 20 kV, 50 mbar/5 s, 20 °C, detection at 237 nm. | Molecular mechanics (MM2) and molecular dynamics simulations/Semiempirical method PM3 | Hydrogen bond, dipole-dipole, and π-π. | [ |
| Terbutalin | heptakis {2,6-di- | Phosphate buffer 60 mM pH 2.5, 10 kV, 0.5 psi/5 s, detection at 210 nm. | Hybrid method ONIOM2: Semiempirical PM3/DFT (B3LYP/6-31G(d,p)) | Electrostatic interactions and hydrogen bonding | [ |
Figure 9Electropherogram related to conditions optimized for enantioseparation of amlodipine and diastereoisomeric complexes obtained via DFT calculations (B97D/6-31G(d,p)) in the aqueous phase. Experimental conditions: 5.5 mg/mL carboxymethyl-β-CD in 50 mM BGE phosphate (NaH2PO4) pH 4.0; uncoated fused-silica capillary 75 µm id × 62.5 cm (71 cm to the detector); hydrodynamic injection using 40 mbar × 4 s; separation voltage at 15 kV; UV detection at 195 nm. Source: Elaborated by the authors themselves (our unpublished results).